Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers.


Journal

Respirology (Carlton, Vic.)
ISSN: 1440-1843
Titre abrégé: Respirology
Pays: Australia
ID NLM: 9616368

Informations de publication

Date de publication:
04 2021
Historique:
revised: 30 09 2020
received: 25 02 2020
accepted: 20 10 2020
pubmed: 10 11 2020
medline: 21 10 2021
entrez: 9 11 2020
Statut: ppublish

Résumé

The relationship between IPF development and environmental factors has not been completely elucidated. Analysing geographic regions of idiopathic pulmonary fibrosis (IPF) cases could help identify those areas with higher aggregation and investigate potential triggers. We hypothesize that cross-analysing location of IPF cases and areas of consistently high air pollution concentration could lead to recognition of environmental risk factors for IPF development. This retrospective study analysed epidemiological and clinical data from 503 patients registered in the Observatory IPF.cat from January 2017 to June 2019. Incident and prevalent IPF cases from the Catalan region of Spain were graphed based on their postal address. We generated maps of the most relevant air pollutant PM2.5 from the last 10 years using data from the CALIOPE air quality forecast system and observational data. In 2018, the prevalence of IPF differed across provinces; from 8.1 cases per 100 000 habitants in Barcelona to 2.0 cases per 100 000 in Girona. The ratio of IPF was higher in some areas. Mapping PM2.5 levels illustrated that certain areas with more industry, traffic and shipping maintained markedly higher PM2.5 concentrations. Most of these locations correlated with higher aggregation of IPF cases. Compared with other risk factors, PM2.5 exposure was the most frequent. In this retrospective study, prevalence of IPF is higher in areas of elevated PM2.5 concentration. Prospective studies with targeted pollution mapping need to be done in specific geographies to compile a broader profile of environmental factors involved in the development of pulmonary fibrosis.

Sections du résumé

BACKGROUND AND OBJECTIVE
The relationship between IPF development and environmental factors has not been completely elucidated. Analysing geographic regions of idiopathic pulmonary fibrosis (IPF) cases could help identify those areas with higher aggregation and investigate potential triggers. We hypothesize that cross-analysing location of IPF cases and areas of consistently high air pollution concentration could lead to recognition of environmental risk factors for IPF development.
METHODS
This retrospective study analysed epidemiological and clinical data from 503 patients registered in the Observatory IPF.cat from January 2017 to June 2019. Incident and prevalent IPF cases from the Catalan region of Spain were graphed based on their postal address. We generated maps of the most relevant air pollutant PM2.5 from the last 10 years using data from the CALIOPE air quality forecast system and observational data.
RESULTS
In 2018, the prevalence of IPF differed across provinces; from 8.1 cases per 100 000 habitants in Barcelona to 2.0 cases per 100 000 in Girona. The ratio of IPF was higher in some areas. Mapping PM2.5 levels illustrated that certain areas with more industry, traffic and shipping maintained markedly higher PM2.5 concentrations. Most of these locations correlated with higher aggregation of IPF cases. Compared with other risk factors, PM2.5 exposure was the most frequent.
CONCLUSION
In this retrospective study, prevalence of IPF is higher in areas of elevated PM2.5 concentration. Prospective studies with targeted pollution mapping need to be done in specific geographies to compile a broader profile of environmental factors involved in the development of pulmonary fibrosis.

Identifiants

pubmed: 33167075
doi: 10.1111/resp.13973
doi:

Substances chimiques

Air Pollutants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-359

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2020 Asian Pacific Society of Respirology.

Références

Xaubet A, Ancochea J, Bollo E, Fernández-Fabrellas E, Franquet T, Molina-Molina M, Montero MA, Serrano-Mollar A. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch. Bronconeumol. 2013; 49: 343-53.
Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur. Respir. J. 2015; 46: 795-806.
Hoyer N, Prior TS, Bendstrup E, Wilcke T, Shaker SB. Risk factors for diagnostic delay in idiopathic pulmonary fibrosis. Respir. Res. 2019; 20: 103.
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier J-F, Flaherty KR, Lasky JA et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
Margaritopoulos GA, Romagnoli M, Poletti V, Siafakas NM, Wells AU, Antoniou KM. Recent advances in the pathogenesis and clinical evaluation of pulmonary fibrosis. Eur. Respir. Rev. 2012; 21: 48-56.
Cho CC, Hsieh WY, Tsai CH, Chen CY, Chang HF, Lin CS. In vitro and in vivo experimental studies of PM 2.5 on disease progression. Int. J. Environ. Res. Public Health 2018; 15: 1-26.
Wang H, Song L, Ju W, Wang X, Dong L, Zhang Y, Ping Y, Yang C, Li F. The acute airway inflammation induced by PM2.5 exposure and the treatment of essential oils in Balb/c mice. Sci. Rep. 2017; 7: 44256.
Conti S, Harari S, Caminati A, Zanobetti A, Schwartz JD, Bertazzi PA, Cesana G, Madotto F. The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy. Eur. Respir. J. 2018; 51: 1700397.
Viegi G, Maio S, Pistelli F, Baldacci S, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease: health effects of air pollution. Respirology 2006; 11: 523-32.
Ko FWS, DSC H. Air pollution and chronic obstructive pulmonary disease. Respirology 2012; 17: 395-401.
Gowers AM, Cullinan P, Ayres JG, Anderson HR, Strachan DP, Holgate ST, Mills IC, Maynard RL. Does outdoor air pollution induce new cases of asthma? Biological plausibility and evidence; a review. Respirology 2012; 17: 887-98.
Siroux V, Crestani B. Is chronic exposure to air pollutants a risk factor for the development of idiopathic pulmonary fibrosis? Eur. Respir. J. 2018; 51: 1702663.
Johannson KA, Vittinghoff E, Lee K, Balmes JR, Ji W, Kaplan GG, Kim DS, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis associated with air pollution exposure. Eur. Respir. J. 2014; 43: 1124-31.
Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, Collard HR. Air pollution exposure is associated with lower lung function, but not changes in lung function, in patients with idiopathic pulmonary fibrosis. Chest 2018; 154: 119-25.
Xing Y-F, Xu Y-H, Shi M-H, Lian Y-X. The impact of PM2.5 on the human respiratory system. J. Thorac. Dis. 2016; 8: E69-74.
World Medical Association. 64th WMA General Assembly, Fortaleza, Brazil. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. 2013. [Accessed 18 Feb 2020.] Available from URL: https://www.wma.net/wp-content/uploads/2016/11/DoH-Oct2013-JAMA.pdf
Molina-Molina M, Agusti A, Crestani B, Schwartz DA, Königshoff M, Chambers RC, Maher TM, Faner R, Mora AL, Rojas M et al. Towards a global initiative for fibrosis treatment (GIFT). ERJ Open Res. 2017; 3: 1-7.
Sociales S. United Nations Second World Assembly on Ageing. Geneva: Assembly, 2002. [Accessed 22 Oct 2020.] Available from URL: http://undocs.org/A/CONF.197/9
World Health Organization. Air Quality Guidelines. Global update 2005. Geneva: World Health Organization, 2006. [Accessed 22 Oct 2020.] Available from URL: https://www.euro.who.int/en/health-topics/environment-and-health/Housing-and-health/publications/pre-2009/air-quality-guidelines.-global-update-2005.-particulate-matter,-ozone,-nitrogen-dioxide-and-sulfur-dioxide
Seinfeld JH. In: Pandis SN (ed) Atmospheric Chemistry and Physics: From Air Pollution to Climate Change, 3rd edn. Hoboken, NJ, Wiley, 2016.
Baldasano JM, Pay MT, Jorba O, Gassó S, Jiménez-Guerrero P. An annual assessment of air quality with the CALIOPE modeling system over Spain. Sci. Total Environ. 2011; 409: 2163-78.
Aguilera I, Basagaña X, Pay MT, Agis D, Bouso L, Foraster M, Rivera M, Baldasano J, Kúnzli N. Evaluation of the CALIOPE air quality forecasting system for epidemiological research: the example of NO2 in the province of Girona (Spain). Atmos. Environ. 2013; 72: 134-41.
Pay MT, Jiménez-Guerrero P, Baldasano JM. Implementation of resuspension from paved roads for the improvement of CALIOPE air quality system in Spain. Atmos. Environ. 2011; 45: 802-7.
Pay MT, Jiménez-Guerrero P, Jorba O, Basart S, Querol X, Pandolfi M, Baldasano JM. Spatio-temporal variability of concentrations and speciation of particulate matter across Spain in the CALIOPE modeling system. Atmos. Environ. 2012; 46: 376-96.
Guevara M, Martínez F, Arévalo G, Gassó S, Baldasano J. An improved system for modelling Spanish emissions: HERMESv2.0. Atmos. Environ. 2013; 81: 209-21.
Skamarock WC, Klemp JB. A time-split nonhydrostatic atmospheric model for weather research and forecasting applications. J. Comput. Phys. 2007; 227: 3465-85.
Byun D, Schere KL. Review of the governing equations, computational algorithms, and other components of the Models-3 Community Multiscale Air Quality (CMAQ) modeling system. Appl. Mech. Rev. 2006; 59: 51-77.
Basart S, Pérez C, Nickovic S, Cuevas E, Baldasano J. Development and evaluation of the BSC-DREAM8b dust regional model over Northern Africa, the Mediterranean and the Middle East. Tellus B Chem. Phys. Meteorol. 2012; 64: 18539.
Akita Y, Baldasano JM, Beelen R, Cirach M, De Hoogh K, Hoek G, Nieuwenhuijsen M, Serre ML, de Nazelle A. Large scale air pollution estimation method combining land use regression and chemical transport modeling in a geostatistical framework. Environ. Sci. Technol. 2014; 48: 4452-9.
Glahn B. Objective analysis of MOS forecasts and observations. 92nd American Meteorological Society Annual Meeting, 21st Conference on Probability Statistics in the Atmospheric Sciences; 22-26 Jan 2012, New Orleans, LA. Silver Spring, MD: Meteorological Development Laboratory, National Weather Service, 2012; 1-11.
Johannson KA. Air pollution exposure and IPF: prevention when there is no cure. Thorax 2018; 73: 103-4.
Miri M, Nazarzadeh M, Alahabadi A, Ehrampoush MH, Rad A, Lotfi MH, Sheikhha MH, Sakhvidi MJZ, Nawrot TS, Dadvand P. Air pollution and telomere length in adults: a systematic review and meta-analysis of observational studies. Environ. Pollut. 2019; 244: 636-47.
Sesé L, Nunes H, Cottin V, Sanyal S, Didier M, Carton Z, Israel-Biet D, Crestani B, Cadranel J, Wallaert B et al. Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. Thorax 2018; 73: 145-50.
Winterbottom CJ, Shah RJ, Patterson KC, Kreider ME, Panettieri RA, Rivera-Lebron B, Miller WT, Litzky LA, Penning TM, Heinlen K et al. Exposure to ambient particulate matter is associated with accelerated functional decline in idiopathic pulmonary fibrosis. Chest 2018; 153: 1221-8.
Mäkelä K, Ollila H, Sutinen E, Vuorinen V, Peltola E, Kaarteenaho R, Myllärniemi M. Inorganic particulate matter in the lung tissue of idiopathic pulmonary fibrosis patients reflects population density and fine particle levels. Ann. Diagn. Pathol. 2019; 40: 136-42.

Auteurs

Jessica Germaine Shull (JG)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Maria Teresa Pay (MT)

Barcelona Supercomputing Center, BSC, c/Jordi Girona, 29,, Barcelona, Spain.

Carla Lara Compte (C)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Miriam Olid (M)

Barcelona Supercomputing Center, BSC, c/Jordi Girona, 29,, Barcelona, Spain.

Guadalupe Bermudo (G)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Karina Portillo (K)

ILD Multidisciplinary Unit, University Hospital Trias i Pujol, Badalona, Spain.

Jacobo Sellarés (J)

ILD Multidisciplinary Unit, Hospital Clínic of Barcelona, IDIBAPS, Barcelona, Spain.

Eva Balcells (E)

Respiratory Medicine Department, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona, Spain.

Vanesa Vicens-Zygmunt (V)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Lurdes Planas-Cerezales (L)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Diana Badenes-Bonet (D)

Respiratory Medicine Department, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Hospital del Mar, Barcelona, Spain.
School of Health & Life Sciences, Pompeu Fabra University (UPF), Barcelona, Spain.
CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Rosana Blavia (R)

Respiratory Department, Hospital Moises Broggi, San Joan Despi, Spain.

Pilar Rivera-Ortega (P)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Amalia Moreno (A)

Respiratory Department, Hospital Parc Taulí, Sabadell, Spain.

Jordi Sans (J)

Respiratory Department, Consorci Sanitari de Terrassa, Terrassa, Spain.

Damià Perich (D)

Respiratory Department, Consorci Sanitari de Terrassa, Terrassa, Spain.

Silvia Barril (S)

Respiratory Department, Hospital Arnau de Vilanova, Lleida, Spain.

Leonardo Esteban (L)

Respiratory Department, Hospital Joan XXIII, Tarragona, Spain.

Laia Garcia-Bellmunt (L)

Respiratory Department, Hospital Sant Joan, Reus, Spain.

Jordi Esplugas (J)

Respiratory Department, Hospital de Martorell, Barcelonès, Spain.

Guillermo Suarez-Cuartin (G)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Jaume Bordas-Martinez (J)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Diego Castillo (D)

ILD Multidisciplinary Unit, Hospital Sant Pau i Santa Creu, Barcelona, Spain.

Rosa Jolis (R)

Respiratory Department, Hospital de Figueres, Figueres, Spain.

Inma Salvador (I)

Respiratory Department, Hospital de Tortosa, Tortosa, Spain.

Saioa Eizaguirre Anton (S)

Respiratory Department, Hospital Trueta de Girona, Girona, Spain.

Ana Villar (A)

ILD Multidisciplinary Unit, Hospital Vall d'Hebron, Barcelona, Spain.

Alejandro Robles-Perez (A)

Respiratory Department, Hospital de Mataró, Mataró, Spain.

M Josefa Cardona (MJ)

Respiratory Department, Hospital de Igualada, Igualada, Spain.

Enric Barbeta (E)

Respiratory Department, Hospital de Granollers, Granollers, Spain.

Maria Guadalupe Silveira (MG)

Respiratory Department, Parc Sanitari Sant Joan de Déu, Sant Boi, Spain.

Claudia Guevara (C)

Respiratory Department, Hospital Sant Camil, Vilanova, Spain.

Jordi Dorca (J)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Antoni Rosell (A)

ILD Multidisciplinary Unit, University Hospital Trias i Pujol, Badalona, Spain.
CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.
Translational Respiratory Research Group, Institut de Recerca Germans Trias i Pujol (IGTP), Badalona, Spain.

Patricio Luburich (P)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Roger Llatjós (R)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.

Oriol Jorba (O)

Barcelona Supercomputing Center, BSC, c/Jordi Girona, 29,, Barcelona, Spain.

Maria Molina-Molina (M)

ILD Multidisciplinary Unit, Bellvitge University Hospital, IDIBELL, Hospitalet de Llobregat, Spain.
CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH